Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Seasoned pharma leader recognized for driving sales excellence, marketing strategy, and business growth
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
The company recycled approximately 100 kilograms of textile waste, undertook plantation activities, and encouraged employees to adopt environmentally responsible practices
Targeting deadly drug-resistant acinetobacter infections
Day-care model aimed at providing specialized psychological support for women during pregnancy and motherhood
Subscribe To Our Newsletter & Stay Updated
